Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Inclusion Criteria: * Age 18 to 54 years * Diagnosis of AD as defined by Hanifin and Rajka (1980) criteria for AD * History of AD for ≥1 year * Subjects who have a recent history of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable * AD involvement of ≥10% body surface area at screening and baseline * An EASI score of ≥12 at screening and 16 at baseline * An IGA score of ≥3 at screening and at baseline * Subjects must have applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation Exclusion Criteria: * Subjects for whom administration of the meningococcal vaccine provided in this trial is contraindicated or medically inadvisable, according to local label of the vaccine * Subjects for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this trial is contraindicated or medically inadvisable, according to local label of the vaccine * Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment * Use of tanning beds or phototherapy within 6 weeks prior to randomization * Treatment with systemic immunosuppressive/immunomodulating medications and/or systemic corticosteroids within 4 weeks prior to randomization * Treatment with the topical medications topical corticosteroids (TCS), topical calcineurin inhibitor (TCI) or phosphodiesterase 4 (PDE-4) inhibitor within 2 weeks prior to randomization * Receipt of any vaccine (except influenza virus vaccines) within 3 months prior to screening, any meningococcal vaccine within 1 year prior to screening, or any tetanus-, diphtheria-, or pertussis-containing vaccine within 5 years prior to screening * Receipt of any marketed (i.e. immunoglobulin, anti-IgE) or investigational biologic agent, including dupilumab * History of any active skin infection within 1 week prior to randomization * History of a clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to randomization